Akihiro Fujimoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Akihiro Fujimoto has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Toshiaki Saeki
Department of Breast Oncology Saitama Medical University International Medical Center Hidaka Saitama Japan
11 shared publicationsKazuo Matsuura
Department of Breast Oncology Saitama Medical University International Medical Center Hidaka Saitama Japan
9 shared publicationsTakahiro Hasebe
9 shared publicationsAsami Nukui
Department of Breast Oncology Saitama Medical University International Medical Center Hidaka Saitama Japan
8 shared publicationsAya Asano
Department of Breast Oncology Saitama Medical University Hospital Moroyama‐machi, Iruma‐gun Saitama Japan
8 shared publicationsAkihiko Osaki
7 shared publications
Latest Publications
- Open Access
- 7 November 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (11)
Efficacy and Safety of Datopotamab Deruxtecan From a Single‐Institution Experience in Hormone Receptor–Positive, HER2 ‐Negative Metastatic Breast Cancer After Multiple Prior Therapies Including Antibody–Drug Conjugates
Background: Datopotamab deruxtecan (Dato‐DXd) is a trophoblast cell surface antigen 2 (TROP2)–directed antibody–drug conjugate (ADC) with a topoisomerase I inhibitor payload and was approved by the Japan Pharmaceuticals and Medical Devices Agency in 2025 for patients with unresectable or recurrent hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2−) breast cancer previously treated with chemotherapy. In the pivotal TROPION‐Breast01 trial, most patients had received 1 or 2 prior systemic regimens. However, in routine clinical practice, Dato‐DXd is often used in heavily pretreated patients, including those with prior ADC exposure. We evaluated the efficacy and safety of Dato‐DXd in this population. Methods: We retrospectively analyzed 18 patients with HR+/HER2− metastatic or recurrent breast cancer who received Dato‐DXd at our institution between May and December 2025. Clinical data from electronic medical records were reviewed to assess treatment efficacy and treatment‐related adverse events (TRAEs). Results: All patients were female, with a median age of 56 years (range, 48–81). Patients were heavily pretreated, with a median of seven prior systemic treatment lines (range, 2–11); 72.2% had previously received trastuzumab deruxtecan (T‐DXd). Median real‐world progression‐free survival (rwPFS) was 3.2 months. Patients with prior T‐DXd exposure had significantly shorter rwPFS than T‐DXd–naïve patients (2.8 vs. 6.4 months, p < 0.01). TRAEs were generally mild and manageable. The most common TRAEs included alopecia, fatigue, constipation, stomatitis, nausea, and elevated liver transaminases. Five patients required dose reductions, but no treatment discontinuations or fatal events occurred. No cases of interstitial lung disease occurred. Conclusions: In this cohort of heavily pretreated HR+/HER2− metastatic or recurrent breast cancer, Dato‐DXd showed limited clinical activity compared with clinical trials, particularly among patients previously treated with T‐DXd. Nevertheless, Dato‐DXd was safely administered with toxicity management. Further real‐world studies are needed to optimize patient selection and treatment sequencing.
- 7 November 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (11)
Open AccessEfficacy and Safety of Datopotamab Deruxtecan From a Single‐Institution Experience in Hormone Receptor–Positive, HER2 ‐Negative Metastatic Breast Cancer After Multiple Prior Therapies Including Antibody–Drug Conjugates
Background: Datopotamab deruxtecan (Dato‐DXd) is a trophoblast cell surface antigen 2 (TROP2)–directed antibody–drug conjugate (ADC) with a topoisomerase I inhibitor payload and was approved by the Japan Pharmaceuticals and Medical Devices Agency in 2025 for patients with unresectable or recurrent hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2−) breast cancer previously treated with chemotherapy. In the pivotal TROPION‐Breast01 trial, most patients had received 1 or 2 prior systemic regimens. However, in routine clinical practice, Dato‐DXd is often used in heavily pretreated patients, including those with prior ADC exposure. We evaluated the efficacy and safety of Dato‐DXd in this population. Methods: We retrospectively analyzed 18 patients with HR+/HER2− metastatic or recurrent breast cancer who received Dato‐DXd at our institution between May and December 2025. Clinical data from electronic medical records were reviewed to assess treatment efficacy and treatment‐related adverse events (TRAEs). Results: All patients were female, with a median age of 56 years (range, 48–81). Patients were heavily pretreated, with a median of seven prior systemic treatment lines (range, 2–11); 72.2% had previously received trastuzumab deruxtecan (T‐DXd). Median real‐world progression‐free survival (rwPFS) was 3.2 months. Patients with prior T‐DXd exposure had significantly shorter rwPFS than T‐DXd–naïve patients (2.8 vs. 6.4 months, p < 0.01). TRAEs were generally mild and manageable. The most common TRAEs included alopecia, fatigue, constipation, stomatitis, nausea, and elevated liver transaminases. Five patients required dose reductions, but no treatment discontinuations or fatal events occurred. No cases of interstitial lung disease occurred. Conclusions: In this cohort of heavily pretreated HR+/HER2− metastatic or recurrent breast cancer, Dato‐DXd showed limited clinical activity compared with clinical trials, particularly among patients previously treated with T‐DXd. Nevertheless, Dato‐DXd was safely administered with toxicity management. Further real‐world studies are needed to optimize patient selection and treatment sequencing.
- Open Access
- 10 October 2026
- Published by S. Karger AG in Case Reports in Oncology
Matrix-Producing Carcinoma of the Breast: A Rare Triple-Negative, Vimentin-Positive Tumor With an Immune-Cold Microenvironment: A Case Report
Introduction: Matrix-producing carcinoma (MPC) is a rare subtype of metaplastic breast carcinoma characterized by a direct transition from epithelial carcinoma cells to a cartilaginous or osseous matrix. MPC typically exhibits a triple-negative immunophenotype and frequently expresses mesenchymal markers such as vimentin. However, data regarding its immune microenvironment remain limited. Case Presentation: A woman in her 70s presented with a palpable mass in the right breast. Imaging studies demonstrated peripheral enhancement with a central non-enhancing area on contrast-enhanced magnetic resonance imaging, along with partial hypointensity on T2-weighted images. She underwent breast-conserving surgery with sentinel lymph node biopsy, and pathological examination revealed stage IIA (T2N0M0) metaplastic carcinoma of the breast consistent with MPC. Immunohistochemically, the tumor showed a triple-negative phenotype with a high Ki-67 labeling index and strong vimentin expression. Stromal tumor-infiltrating lymphocytes were absent. Programmed death-ligand 1 expression was negative in tumor cells by the 22C3 assay (combined positive score < 1), whereas SP142 staining showed low programmed death-ligand 1 expression in immune cells (IC1, 1–4%). Adjuvant chemotherapy was not administered because of advanced age and patient preference. No recurrence has been observed 18 months after surgery. Conclusion: MPC is a rare breast cancer with distinctive pathological and radiological features. Although based on a single case with short follow-up, this report provides clinically relevant information on this uncommon carcinoma. The immune-cold tumor microenvironment observed in this case may have potential implications for immunotherapy, warranting further investigation.
- 10 October 2026
- Published by S. Karger AG in Case Reports in Oncology
Open AccessMatrix-Producing Carcinoma of the Breast: A Rare Triple-Negative, Vimentin-Positive Tumor With an Immune-Cold Microenvironment: A Case Report
Introduction: Matrix-producing carcinoma (MPC) is a rare subtype of metaplastic breast carcinoma characterized by a direct transition from epithelial carcinoma cells to a cartilaginous or osseous matrix. MPC typically exhibits a triple-negative immunophenotype and frequently expresses mesenchymal markers such as vimentin. However, data regarding its immune microenvironment remain limited. Case Presentation: A woman in her 70s presented with a palpable mass in the right breast. Imaging studies demonstrated peripheral enhancement with a central non-enhancing area on contrast-enhanced magnetic resonance imaging, along with partial hypointensity on T2-weighted images. She underwent breast-conserving surgery with sentinel lymph node biopsy, and pathological examination revealed stage IIA (T2N0M0) metaplastic carcinoma of the breast consistent with MPC. Immunohistochemically, the tumor showed a triple-negative phenotype with a high Ki-67 labeling index and strong vimentin expression. Stromal tumor-infiltrating lymphocytes were absent. Programmed death-ligand 1 expression was negative in tumor cells by the 22C3 assay (combined positive score < 1), whereas SP142 staining showed low programmed death-ligand 1 expression in immune cells (IC1, 1–4%). Adjuvant chemotherapy was not administered because of advanced age and patient preference. No recurrence has been observed 18 months after surgery. Conclusion: MPC is a rare breast cancer with distinctive pathological and radiological features. Although based on a single case with short follow-up, this report provides clinically relevant information on this uncommon carcinoma. The immune-cold tumor microenvironment observed in this case may have potential implications for immunotherapy, warranting further investigation.
- Open Access
- 22 August 2026
- Published by Elsevier in Clinical Breast Cancer
- Vol. 26 (10) , 52-57
Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response in Triple-Negative Breast Cancer Treated With Neoadjuvant Pembrolizumab Plus Chemotherapy
- 22 August 2026
- Published by Elsevier in Clinical Breast Cancer
- Vol. 26 (10) , 52-57
Open AccessNeutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response in Triple-Negative Breast Cancer Treated With Neoadjuvant Pembrolizumab Plus Chemotherapy
- Open Access
- 13 July 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Baseline peripheral blood immune markers associated with clinical outcomes in patients with advanced breast cancer treated with trastuzumab deruxtecan
Background: Trastuzumab deruxtecan (T-DXd) has demonstrated substantial clinical efficacy in patients with advanced breast cancer; however, predictive and prognostic biomarkers for treatment outcomes remain poorly defined. Host immune status has been reported to influence the efficacy of various systemic therapies, but its clinical significance in patients treated with T-DXd is not yet fully understood. Methods: We conducted a retrospective, single-center study of patients with breast cancer who received T-DXd. Their baseline peripheral blood immune markers—including absolute lymphocyte count (ALC), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio—were evaluated prior to treatment initiation. Time-to-treatment failure (TTF) and overall survival (OS) were analyzed using Kaplan–Meier methods and Cox proportional hazards models. Results: A total of 126 patients were included in the study. Univariate analyses showed that low ALC and high NLR were associated with shorter TTF and OS. In multivariate analyses adjusted for relevant clinical factors, low ALC and high NLR remained associated with shorter TTF and OS. Conclusions: Baseline peripheral blood immune markers, particularly ALC and NLR, may be associated with clinical outcomes in patients with breast cancer treated with T-DXd. These readily available markers may have potential clinical utility and warrant further prospective validation.
- 13 July 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Open AccessBaseline peripheral blood immune markers associated with clinical outcomes in patients with advanced breast cancer treated with trastuzumab deruxtecan
Background: Trastuzumab deruxtecan (T-DXd) has demonstrated substantial clinical efficacy in patients with advanced breast cancer; however, predictive and prognostic biomarkers for treatment outcomes remain poorly defined. Host immune status has been reported to influence the efficacy of various systemic therapies, but its clinical significance in patients treated with T-DXd is not yet fully understood. Methods: We conducted a retrospective, single-center study of patients with breast cancer who received T-DXd. Their baseline peripheral blood immune markers—including absolute lymphocyte count (ALC), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio—were evaluated prior to treatment initiation. Time-to-treatment failure (TTF) and overall survival (OS) were analyzed using Kaplan–Meier methods and Cox proportional hazards models. Results: A total of 126 patients were included in the study. Univariate analyses showed that low ALC and high NLR were associated with shorter TTF and OS. In multivariate analyses adjusted for relevant clinical factors, low ALC and high NLR remained associated with shorter TTF and OS. Conclusions: Baseline peripheral blood immune markers, particularly ALC and NLR, may be associated with clinical outcomes in patients with breast cancer treated with T-DXd. These readily available markers may have potential clinical utility and warrant further prospective validation.
- Open Access
- 1 July 2026
- Published by International Institute of Anticancer Research in Cancer Diagnosis & Prognosis
- Vol. 6 (4) , 682-691
Baseline Neutrophil-to-Lymphocyte Ratio Predicts Overall Survival in PD-L1-positive Advanced Triple-negative Breast Cancer With Immune-checkpoint-inhibitor Treatment
Background/Aim: Immune checkpoint inhibitors (ICIs) have improved clinical outcomes in patients with advanced triple-negative breast cancer (TNBC); however, substantial heterogeneity exists in treatment durability and survival. Simple blood-based immune markers may provide prognostic information; however, their clinical relevance in ICI-treated TNBC remain unclear. Patients and Methods: We conducted a retrospective single-center study of patients with advanced TNBC treated with ICIs, including atezolizumab or pembrolizumab. Baseline peripheral immune markers – absolute lymphocyte count (ALC) and neutrophil-to-lymphocyte ratio (NLR) – were evaluated prior to treatment initiation. Time-to-treatment failure (TTF) and overall survival (OS) were analyzed using the Kaplan–Meier method and Cox proportional hazards model. Results: A total of 43 patients were included. In the Kaplan–Meier analysis, high baseline NLR was significantly associated with both shorter TTF and OS. Low baseline ALC was significantly associated with shorter TTF but not with OS. In the multivariate Cox proportional hazards analysis of TTF, no baseline clinical or immune parameters were identified as independent prognostic factors. In contrast, multivariate analysis for OS demonstrated that high baseline NLR was the only independent prognostic factor. Conclusion: NLR was independently associated with OS, suggesting it functions as a prognostic marker of systemic inflammatory and immune balance. In contrast, ALC was associated with treatment durability but not long-term survival, indicating its relevance to treatment tolerance rather than survival outcomes. These findings highlight the clinical utility of simple blood-based immune markers for risk stratification in ICI-treated TNBC.
- 1 July 2026
- Published by International Institute of Anticancer Research in Cancer Diagnosis & Prognosis
- Vol. 6 (4) , 682-691
Open AccessBaseline Neutrophil-to-Lymphocyte Ratio Predicts Overall Survival in PD-L1-positive Advanced Triple-negative Breast Cancer With Immune-checkpoint-inhibitor Treatment
Background/Aim: Immune checkpoint inhibitors (ICIs) have improved clinical outcomes in patients with advanced triple-negative breast cancer (TNBC); however, substantial heterogeneity exists in treatment durability and survival. Simple blood-based immune markers may provide prognostic information; however, their clinical relevance in ICI-treated TNBC remain unclear. Patients and Methods: We conducted a retrospective single-center study of patients with advanced TNBC treated with ICIs, including atezolizumab or pembrolizumab. Baseline peripheral immune markers – absolute lymphocyte count (ALC) and neutrophil-to-lymphocyte ratio (NLR) – were evaluated prior to treatment initiation. Time-to-treatment failure (TTF) and overall survival (OS) were analyzed using the Kaplan–Meier method and Cox proportional hazards model. Results: A total of 43 patients were included. In the Kaplan–Meier analysis, high baseline NLR was significantly associated with both shorter TTF and OS. Low baseline ALC was significantly associated with shorter TTF but not with OS. In the multivariate Cox proportional hazards analysis of TTF, no baseline clinical or immune parameters were identified as independent prognostic factors. In contrast, multivariate analysis for OS demonstrated that high baseline NLR was the only independent prognostic factor. Conclusion: NLR was independently associated with OS, suggesting it functions as a prognostic marker of systemic inflammatory and immune balance. In contrast, ALC was associated with treatment durability but not long-term survival, indicating its relevance to treatment tolerance rather than survival outcomes. These findings highlight the clinical utility of simple blood-based immune markers for risk stratification in ICI-treated TNBC.
- Open Access
FOXM1 Expression in Invasive Ductal Breast Carcinoma of No Special Type: Insights from RNA-seq and Immunohistochemical Analysis
Background: Invasive ductal carcinoma of no special type (IDC-NST) is the most common subtype of breast cancer, characterized by significant clinical heterogeneity. Forkhead box M1 (FOXM1) is a key transcription factor involved in cell cycle regulation and tumor progression, but its expression profile and clinical significance in IDC-NST remain incompletely understood. Methods: We analyzed FOXM1 expression in a cohort of 100 IDC-NST patients using RNA sequencing and immunohistochemistry (IHC). FOXM1 mRNA levels were quantified, and protein expression was scored based on the percentage of positive tumor cells. Differentially expressed genes (DEGs) between high and low FOXM1 expression groups were identified, followed by pathway enrichment and protein–protein interaction (PPI) network analyses. The prognostic value of FOXM1 was evaluated by recurrence-free survival (RFS) analysis. Results: FOXM1 protein expression correlated significantly with mRNA abundance in 22 representative cases (p < 0.05). Receiver operating characteristic (ROC) curve analysis identified a cut-off value of 4.954 CPM for FOXM1 mRNA to predict recurrence (AUC = 0.642). High FOXM1 expression was associated with larger tumor size, higher histological grade, and negative hormone receptor status. Patients with high FOXM1 expression exhibited significantly poorer 5-year RFS (73.6% vs. 92.3%, p < 0.001). Multivariate analysis confirmed FOXM1 as an independent prognostic factor (HR 15.26; p = 0.026). Transcriptomic profiling revealed 190 upregulated and 197 downregulated genes in the FOXM1-high group, enriched in cell cycle and mitotic pathways. PPI network analysis positioned FOXM1 as a central hub coordinating genes involved in chromosomal stability and mitosis. Conclusions: FOXM1 overexpression is a strong independent predictor of poor prognosis in IDC-NST and plays a critical role in tumor proliferation and genome integrity. These findings support FOXM1 as a potential prognostic biomarker and therapeutic target, warranting further investigation into FOXM1-targeted therapies for breast cancer management.
Open AccessFOXM1 Expression in Invasive Ductal Breast Carcinoma of No Special Type: Insights from RNA-seq and Immunohistochemical Analysis
Background: Invasive ductal carcinoma of no special type (IDC-NST) is the most common subtype of breast cancer, characterized by significant clinical heterogeneity. Forkhead box M1 (FOXM1) is a key transcription factor involved in cell cycle regulation and tumor progression, but its expression profile and clinical significance in IDC-NST remain incompletely understood. Methods: We analyzed FOXM1 expression in a cohort of 100 IDC-NST patients using RNA sequencing and immunohistochemistry (IHC). FOXM1 mRNA levels were quantified, and protein expression was scored based on the percentage of positive tumor cells. Differentially expressed genes (DEGs) between high and low FOXM1 expression groups were identified, followed by pathway enrichment and protein–protein interaction (PPI) network analyses. The prognostic value of FOXM1 was evaluated by recurrence-free survival (RFS) analysis. Results: FOXM1 protein expression correlated significantly with mRNA abundance in 22 representative cases (p < 0.05). Receiver operating characteristic (ROC) curve analysis identified a cut-off value of 4.954 CPM for FOXM1 mRNA to predict recurrence (AUC = 0.642). High FOXM1 expression was associated with larger tumor size, higher histological grade, and negative hormone receptor status. Patients with high FOXM1 expression exhibited significantly poorer 5-year RFS (73.6% vs. 92.3%, p < 0.001). Multivariate analysis confirmed FOXM1 as an independent prognostic factor (HR 15.26; p = 0.026). Transcriptomic profiling revealed 190 upregulated and 197 downregulated genes in the FOXM1-high group, enriched in cell cycle and mitotic pathways. PPI network analysis positioned FOXM1 as a central hub coordinating genes involved in chromosomal stability and mitosis. Conclusions: FOXM1 overexpression is a strong independent predictor of poor prognosis in IDC-NST and plays a critical role in tumor proliferation and genome integrity. These findings support FOXM1 as a potential prognostic biomarker and therapeutic target, warranting further investigation into FOXM1-targeted therapies for breast cancer management.
- Open Access
- 11 August 2025
- Published by Oxford University Press (OUP) in Oxford Medical Case Reports
- Vol. 2025 (8)
G-CSF-induced Aortitis in an elderly woman successfully managed with prednisolone: a case report and literature review
Cancer incidence among old is increasing. Since age is important risk factor for febrile neutropenia (FN), use of granulocyte-colony stimulating factor (G-CSF) and its complication is clinically important. A 72-year old woman has completed definitive surgery for left breast cancer and was started on postoperative chemotherapy. After 12 doses of paclitaxel, she received 1st cycle of epirubicin and cyclophosphamide (day 1), and pegfilgrastim, a pegylated G-CSF to decrease the risk of FN (day 2). On day 13, she was admitted due to persistent fever since day 9. Laboratory tests revealed elevated neutrophil counts and C-reactive protein. Despite empirical antibiotics, her fever persisted and severe back pain developed (day 15). Contrast-enhanced computed tomography revealed wall thickening and increased density around the aortic arch and brachiocephalic artery. Diagnosis of pegfilgrastim-induced vasculitis was made after excluding autoimmune vasculitis. Prednisolone (60 mg/day) was administered and the fever and back pain subsided the following day.
- 11 August 2025
- Published by Oxford University Press (OUP) in Oxford Medical Case Reports
- Vol. 2025 (8)
Open AccessG-CSF-induced Aortitis in an elderly woman successfully managed with prednisolone: a case report and literature review
Cancer incidence among old is increasing. Since age is important risk factor for febrile neutropenia (FN), use of granulocyte-colony stimulating factor (G-CSF) and its complication is clinically important. A 72-year old woman has completed definitive surgery for left breast cancer and was started on postoperative chemotherapy. After 12 doses of paclitaxel, she received 1st cycle of epirubicin and cyclophosphamide (day 1), and pegfilgrastim, a pegylated G-CSF to decrease the risk of FN (day 2). On day 13, she was admitted due to persistent fever since day 9. Laboratory tests revealed elevated neutrophil counts and C-reactive protein. Despite empirical antibiotics, her fever persisted and severe back pain developed (day 15). Contrast-enhanced computed tomography revealed wall thickening and increased density around the aortic arch and brachiocephalic artery. Diagnosis of pegfilgrastim-induced vasculitis was made after excluding autoimmune vasculitis. Prednisolone (60 mg/day) was administered and the fever and back pain subsided the following day.
- Open Access
- 23 June 2022
- Published by Oxford University Press (OUP) in Oxford Medical Case Reports
- Vol. 2022 (6) , omac063
Carney complex with multiple breast tumours including breast cancer: a case report
Carney complex (CNC) is a rare multiple tumour syndrome characterized by cutaneous pigmented lesions, myxoma and endocrine tumours, among others, and is inherited as an autosomal dominant trait. Protein kinase cAMP-dependent type I regulatory subunit alpha (PRKAR1A) is known to be the responsible gene. Breast myxomatosis and ductal adenoma, which are regarded as benign, are well-known mammary lesions of CNC and are included in the main diagnostic criteria. In this case, a 59-year-old woman with repeated cardiac myxoma was diagnosed with CNC with PRKAR1A mutation. She also had three multiple breast tumours bilaterally: breast cancer, adenomyoepithelioma and intraductal papilloma. In mammary lesions of CNC, attention should be paid to benign lesions, such as breast myxomatosis or ductal adenomas, and the development of breast cancer or breast tumours with malignant potential. Mammary lesions should be aggressively scrutinized and considered for resection, as required.
- 23 June 2022
- Published by Oxford University Press (OUP) in Oxford Medical Case Reports
- Vol. 2022 (6) , omac063
Open AccessCarney complex with multiple breast tumours including breast cancer: a case report
Carney complex (CNC) is a rare multiple tumour syndrome characterized by cutaneous pigmented lesions, myxoma and endocrine tumours, among others, and is inherited as an autosomal dominant trait. Protein kinase cAMP-dependent type I regulatory subunit alpha (PRKAR1A) is known to be the responsible gene. Breast myxomatosis and ductal adenoma, which are regarded as benign, are well-known mammary lesions of CNC and are included in the main diagnostic criteria. In this case, a 59-year-old woman with repeated cardiac myxoma was diagnosed with CNC with PRKAR1A mutation. She also had three multiple breast tumours bilaterally: breast cancer, adenomyoepithelioma and intraductal papilloma. In mammary lesions of CNC, attention should be paid to benign lesions, such as breast myxomatosis or ductal adenomas, and the development of breast cancer or breast tumours with malignant potential. Mammary lesions should be aggressively scrutinized and considered for resection, as required.
- Open Access
- 21 September 2021
- Published by BMJ in BMJ Case Reports
- Vol. 14 (9) , e242742
Hidden breast cancer after breast augmentation, not presenting as a hypoechoic mass lesion, diagnosed using colour Doppler ultrasound
The main concern after breast augmentation with silicone injection is that silicone granulomas make it difficult to detect breast cancer. A case of breast cancer was diagnosed using colour Doppler ultrasound (CD) to detect an non-palpable mass not presenting as a hypoechoic mass lesion. An 83-year-old woman was incidentally found to have a lesion in her right breast, which was injected with silicone, showing 18F-fluorodeoxyglucose (FDG) uptake; the lesion was suspected to be breast cancer or silicone granuloma. A mass at the FDG uptake site was not detected on ultrasonography (US); however, observation using CD revealed a slightly hypoechoic area with hypervascularity. Core needle biopsy showed invasive ductal carcinoma. Patients in whom US does not reveal lesions after breast augmentation with silicone injection should undergo CD to detect hypervascularised tissue. To prevent false-negative biopsy results, CD is essential to detect cancer at suspected sites.
- 21 September 2021
- Published by BMJ in BMJ Case Reports
- Vol. 14 (9) , e242742
Open AccessHidden breast cancer after breast augmentation, not presenting as a hypoechoic mass lesion, diagnosed using colour Doppler ultrasound
The main concern after breast augmentation with silicone injection is that silicone granulomas make it difficult to detect breast cancer. A case of breast cancer was diagnosed using colour Doppler ultrasound (CD) to detect an non-palpable mass not presenting as a hypoechoic mass lesion. An 83-year-old woman was incidentally found to have a lesion in her right breast, which was injected with silicone, showing 18F-fluorodeoxyglucose (FDG) uptake; the lesion was suspected to be breast cancer or silicone granuloma. A mass at the FDG uptake site was not detected on ultrasonography (US); however, observation using CD revealed a slightly hypoechoic area with hypervascularity. Core needle biopsy showed invasive ductal carcinoma. Patients in whom US does not reveal lesions after breast augmentation with silicone injection should undergo CD to detect hypervascularised tissue. To prevent false-negative biopsy results, CD is essential to detect cancer at suspected sites.
- Open Access
- 13 September 2021
- Published by Oxford University Press (OUP) in Oxford Medical Case Reports
- Vol. 2021 (9) , 351-354
Early HER2-positive breast cancer arising from a fibroadenoma: a case report
Breast cancer arising from fibroadenoma (FA) is rare, in which almost all reported cases are human epidermal growth factor receptor 2 (HER2)-negative. This is the first report to describe a case of HER2-positive breast cancer arising from FA that was treated with chemotherapy plus anti-HER2 therapy. In this early case, upfront surgery outcomes guided the selection of appropriate systemic therapy. A 31-year-old woman previously diagnosed with FA experienced tumor growth. Core needle biopsy and imaging studies confirmed a diagnosis of stage IIA HER2-positive invasive ductal carcinoma (IDC) with no evidence of lymph node metastasis (cT2N0M0). Breast-conserving surgery was performed. Pathological diagnosis revealed stage IA IDC with a predominant intraductal component (pT1aN0M0), arising from FA. In conclusion, we encountered an extremely rare case of HER2-positive breast cancer arising from FA in which pathological infiltration was difficult to predict based on preoperative imaging.
- 13 September 2021
- Published by Oxford University Press (OUP) in Oxford Medical Case Reports
- Vol. 2021 (9) , 351-354
Open AccessEarly HER2-positive breast cancer arising from a fibroadenoma: a case report
Breast cancer arising from fibroadenoma (FA) is rare, in which almost all reported cases are human epidermal growth factor receptor 2 (HER2)-negative. This is the first report to describe a case of HER2-positive breast cancer arising from FA that was treated with chemotherapy plus anti-HER2 therapy. In this early case, upfront surgery outcomes guided the selection of appropriate systemic therapy. A 31-year-old woman previously diagnosed with FA experienced tumor growth. Core needle biopsy and imaging studies confirmed a diagnosis of stage IIA HER2-positive invasive ductal carcinoma (IDC) with no evidence of lymph node metastasis (cT2N0M0). Breast-conserving surgery was performed. Pathological diagnosis revealed stage IA IDC with a predominant intraductal component (pT1aN0M0), arising from FA. In conclusion, we encountered an extremely rare case of HER2-positive breast cancer arising from FA in which pathological infiltration was difficult to predict based on preoperative imaging.